Here, we report the development of a chondroitin sulfate-modified liposomal formulation (OPCR-Lip) designed to achieve comprehensive PD-L1 blockade while reprogramming the tumor microenvironment to enhance immune activation. The gene discussed is CD274; the disease is neoplasm.